Danazol relieves refractory pruritus associated with myeloproliterative disorders and other diseases

Luciano Kolodny, Lawrence L. Horstman, Bernd Uwe Sevin, Harvey Brown, Yeon S. Ahn

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Severe pruritus is frequently associated with myeloproliferative and other systemic illnesses, and often fails to respond to conventional measures. We used danazol (Danocrine™), a synthetic attenuated androgen, in the treatment of severe pruritus refractory to conventional therapy. Eight patients had myeloproliferative disorders (MPD), seven had autoimmune disorders, and seven had skin diseases. Danazol at 400-800 mg/day was administered, and previous medications were tapered off. When itching was controlled with danazol alone, the dosage was reduced or discontinued, and resumed if itching recurred. Clinical responses were graded, and side effects were monitored. Overall, in 12 of 22 patients refractory to other measures, itching was controlled with danazol alone. In 10 patients itching returned when danazol was discontinued or dosage was reduced, and was relieved upon resumption or increase of dosage. Danazol therapy was continued for up to 5 years in responders. No serious side effects were observed. Our experience indicates that danazol is a good alternative for patients with severe pruritus associated with myeloproliferative and other systemic disorders.

Original languageEnglish (US)
Pages (from-to)112-116
Number of pages5
JournalAmerican Journal of Hematology
Volume51
Issue number2
DOIs
StatePublished - Feb 1996

Keywords

  • Danazol
  • Myeloproliferative disorder
  • Polycythemia vera
  • Pruritus

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Danazol relieves refractory pruritus associated with myeloproliterative disorders and other diseases'. Together they form a unique fingerprint.

  • Cite this